Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with th...
Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the ful...
Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(0.23) per share. This is a 69.74 percent increase over losses of $(0.76)...
- SEC Filing
Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(0.29) per share. This is a 270.59 percent decrease over earnings of $0.1...
